Ipca Laboratories Ltd.

NSE: IPCALAB | BSE: 524494 | ISIN: INE571A01038 | Industry: Pharmaceuticals
| Mid-range Performer
1412.3000 14.10 (1.01%)
NSE Jan 02, 2026 10:32 AM
Volume: 17,754
 

1412.30
1.01%
ICICI Securities Limited
ICICI Securities Ltd | Retail Equity Research Revenues grew 17.6% YoY to | 783 crore (I-direct estimate: | 781 crore) due to 16.7% growth in domestic formulations to | 323 crore (I-direct estimate: | 318 crore) and 25% growth in API to | 192 crore (I-direct estimate: | 175 crore). Export formulations grew 12.3% YoY to | 251 crore (I-direct estimate: | 276 crore) EBITDA margins improved 388 bps to 14.0% YoY (I-direct estimate: 15.0%) mainly due to an improvement in gross margins (67.3% vs....
Number of FII/FPI investors decreased from 270 to 254 in Sep 2025 qtr
More from Ipca Laboratories Ltd.
Recommended